K. Scarsi

发表

Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART

C. Fletcher, A. Owen, D. Back, 2018, The Journal of antimicrobial chemotherapy.

In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel

A. Owen, H. Kinvig, M. Siccardi, 2021, HIV medicine.

Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women

S. Khoo, C. Nakabiito, M. Boffito, 2010, Journal of acquired immune deficiency syndromes.

Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review

C. Fletcher, A. Podany, Joshua P. Havens, 2019, Clinical Pharmacokinetics.

Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort

E. T. Tchetgen Tchetgen, R. Murphy, P. Kanki, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of Inactive Empiric Antimicrobial Therapy on Inpatient Mortality and Length of Stay

J. Feinglass, M. Postelnick, G. Noskin, 2006, Antimicrobial Agents and Chemotherapy.

Optimizing Treatment Switch for Virologic Failure during First-Line Antiretroviral Therapy in Resource-Limited Settings

I. Adewole, J. Feinglass, B. Taiwo, 2013, Journal of the International Association of Providers of AIDS Care.

Drug–Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV

M. Lamorde, Kristin M. Darin, K. Scarsi, 2016, Drug Safety.

Chronic Hepatitis B Infection: Principles of Therapy

Kristin M. Darin, K. Scarsi, 2009 .

Drug Interactions with Gender-Affirming Hormone Therapy: Focus on Antiretrovirals and Direct Acting Antivirals

A. Tseng, K. Scarsi, L. Cirrincione, 2020, Expert opinion on drug metabolism & toxicology.

Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review

C. Fletcher, A. Podany, Michelle Pham, 2020, Clinical Pharmacokinetics.

Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks

D. Back, S. Cohn, C. Merry, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dolutegravir-induced colitis in an HIV-infected patient.

S. Swindells, U. Sandkovsky, S. Bares, 2016, The Journal of antimicrobial chemotherapy.

Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration

K. Scarsi, M. McLaughlin, Lana Gerzenshtein, 2015, Clinical Drug Investigation.

Clinical implications of antiretroviral drug interactions with warfarin: a case-control study.

M. Postelnick, Kristin M. Darin, K. Scarsi, 2013, The Journal of antimicrobial chemotherapy.

Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection

B. Taiwo, R. Murphy, M. Akanbi, 2012, Expert opinion on pharmacotherapy.

Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.

I. Adewole, S. Parikh, B. Taiwo, 2014, The Journal of antimicrobial chemotherapy.

Predictors of vaccination rates in people living with HIV followed at a specialty care clinic

D. Klepser, S. Bares, K. Scarsi, 2020, Human vaccines & immunotherapeutics.

A Call to Action: The Role of Antiretroviral Stewardship in Inpatient Practice, a Joint Policy Paper of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine

James D. Scott, W. Hardy, N. Pandit, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiretroviral Pharmacokinetics in Pregnant Women

Kristin M. Darin, K. Scarsi, M. McLaughlin, 2015, Pharmacotherapy.

Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay

C. Fletcher, S. Byrareddy, A. Podany, 2018, Scientific Reports.

HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety

C. Fletcher, A. Podany, Sean N. Avedissian, 2020, Drugs.

Hepatotoxicity Associated with Long-versus Short-Course HIV-Prophylactic Nevirapine Use

P. Yarnold, F. Palella, C. Bennett, 2009, Drug safety.

Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors

C. Fletcher, A. Podany, K. Scarsi, 2016, Clinical Pharmacokinetics.

Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide

S. Swindells, C. Fletcher, A. Podany, 2018, AIDS.

The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?

S. Swindells, K. Scarsi, 2021, Journal of the International Association of Providers of AIDS Care.

Breakthrough Candida Infections in Patients Receiving Voriconazole

M. Postelnick, K. Scarsi, J. Flaherty, 2005, The Annals of pharmacotherapy.

Lack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemia.

M. Postelnick, M. Scheetz, M. Bolon, 2006, The Journal of infection.

Drug Interactions in HIV: Nucleoside, Nucleotide, and Nonnucleoside Reverse Transcriptase Inhibitors and Entry Inhibitors

K. Scarsi, L. Cirrincione, 2018 .

Low incidence of renal impairment observed in tenofovir-treated patients.

M. Postelnick, F. Palella, Kristin M. Darin, 2011, The Journal of antimicrobial chemotherapy.

Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy

S. Riddler, S. Cohn, M. Lamorde, 2017, AIDS.

Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.

C. Fletcher, A. Podany, Joshua P. Havens, 2020, The Journal of antimicrobial chemotherapy.

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study

L. Meyn, K. Bunge, D. Bogen, 2020, The Lancet. Microbe.

Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay

C. Fletcher, S. Byrareddy, A. Podany, 2018, Scientific Reports.

Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART

L. Wiesner, G. Odaibo, D. Olaleye, 2020, The Journal of antimicrobial chemotherapy.

Elevated Plasma Concentrations of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors in Patients Coinfected with Human Immunodeficiency Virus and Hepatitis B or C: Case Series and Literature Review

P. Lynch, K. Scarsi, S. M. Robertson, 2005, Pharmacotherapy.

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV

S. Bares, K. Scarsi, 2021, Current opinion in HIV and AIDS.

Chasing the cabotegravir tail: implications for prevention.

K. Scarsi, 2020, The lancet. HIV.

Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines

C. Cohen, C. Morroni, J. Kiarie, 2017, Journal of the International AIDS Society.

Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.

C. Fletcher, A. Owen, S. Cohn, 2023, Contraception.

Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.

C. Fletcher, P. Byakika-Kibwika, M. Siccardi, 2022, The Journal of antimicrobial chemotherapy.

Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives

D. Haas, B. Berzins, F. Aweeka, 2020, Pharmacogenetics and genomics.

A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.

J. Baeten, R. Stalter, D. Erikson, 2019, AIDS.

Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.

B. Berzins, F. Aweeka, S. Swaminathan, 2019, The lancet. HIV.

Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.

A. Owen, M. Siccardi, M. Lamorde, 2019, The Journal of antimicrobial chemotherapy.

Interactions between antiretroviral therapy and vaginally administered contraceptive hormones: A three–arm, pharmacokinetic evaluation

Shobha, B. Berzins, F. Aweeka, 2019 .

Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.

S. Khoo, C. Fletcher, D. Back, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV

C. Achenbach, R. Murphy, K. Scarsi, 2010, Advances in therapy.

Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics

C. Fletcher, A. Podany, K. Scarsi, 2020, Scientific Reports.

Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy

I. Adewole, S. Parikh, B. Taiwo, 2015, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens.

S. Cohn, L. Smeaton, C. Godfrey, 2023, Contraception.

Effect of Differences in MIC Values on Clinical Outcomes in Patients with Bloodstream Infections Caused by Gram-Negative Organisms Treated with Levofloxacin

J. Feinglass, M. Postelnick, M. Scheetz, 2008, Antimicrobial Agents and Chemotherapy.

Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.

B. Brown, P. Kanki, Kristin M. Darin, 2019, The Journal of antimicrobial chemotherapy.

Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant

S. Khoo, D. Back, S. Cohn, 2014, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Protein Binding of Lopinavir and Ritonavir During 4 Phases of Pregnancy: Implications for Treatment Guidelines

M. Hudgens, A. Kashuba, A. Jenkins, 2013, Journal of acquired immune deficiency syndromes.

Antiretrovirals for Human Immunodeficiency Virus Treatment and Prevention in Pregnancy.

M. Mirochnick, K. Scarsi, Kristina M. Brooks, 2023, Obstetrics and gynecology clinics of North America.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Pharmacist-provided rapid HIV testing in two community pharmacies.

M. Klepser, Kristin M. Darin, K. Scarsi, 2015, Journal of the American Pharmacists Association : JAPhA.

Point-of-care testing for infectious diseases: opportunities, barriers, and considerations in community pharmacy.

M. Klepser, Allison M. Dering-Anderson, P. Gubbins, 2014, Journal of the American Pharmacists Association : JAPhA.

Acceptability and Feasibility of a Pharmacist-Led Human Immunodeficiency Virus Pre-Exposure Prophylaxis Program in the Midwestern United States

D. Klepser, H. Sayles, S. Swindells, 2018, Open forum infectious diseases.

Response to Dong et al.

D. Klepser, H. Sayles, S. Swindells, 2020, Open forum infectious diseases.

Midwest pharmacists’ familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV

D. Klepser, H. Sayles, S. Swindells, 2018, PloS one.

1294. Acceptability and Feasibility of a Pharmacist-led Pre-exposure Prophylaxis Program in the Midwestern United States

D. Klepser, S. Swindells, Joshua P. Havens, 2018, Open Forum Infectious Diseases.

Pharmacist participation in medical rounds reduces medication errors.

G. Noskin, Gary A Noskin, Kimberly K Scarsi, 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Low rate of sex-specific analyses in presentations at the Conference of Retroviruses and Opportunistic Infections (CROI) meeting, 2018: Room to improve.

S. Gianella, E. Scully, E. Connick, 2019, Journal of acquired immune deficiency syndromes.

Impact of an Electronic Medical Record on the Incidence of Antiretroviral Prescription Errors and HIV Pharmacist Reconciliation on Error Correction among Hospitalized HIV-Infected Patients

H. Sayles, S. Swindells, R. Batra, 2015, Antiviral therapy.

The impact of gender and pregnancy on antiretroviral therapy for HIV: pharmacokinetic and disease-related differences.

M. Postelnick, K. Scarsi, 2003, The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia.

Consumer interest in community pharmacy HIV screening services.

D. Klepser, M. Klepser, Kristin M. Darin, 2015, Journal of the American Pharmacists Association : JAPhA.

A novel 4-cell in-vitro blood-brain barrier model and its characterization by confocal microscopy and TEER measurement

C. Fletcher, A. Podany, Sean N. Avedissian, 2023, Journal of Neuroscience Methods.

Accumulation of Protease Mutations among Patients Failing Second-Line Antiretroviral Therapy and Response to Salvage Therapy in Nigeria

P. Kanki, C. Onwuamah, Kristin M. Darin, 2013, PloS one.

Adjustment of antimicrobial dosages for continuous venovenous hemofiltration based on patient-specific information.

C. Ghossein, M. Postelnick, M. Scheetz, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Use of ACE Inhibitors as Renoprotective Agents in Medicaid Patients with Diabetes

K. Scarsi, D. Bjornson, 2000, The Annals of pharmacotherapy.

A pharmacokinetic and treatment study of ledipasvir/sofosbuvir in pregnant women with hepatitis C virus

L. Meyn, K. Bunge, D. Bogen, 2019 .